Predictive Value of Microdose Pharmacokinetics

Phase 0 microdose trials are exploratory studies to early assess human pharmacokinetics of new chemical entities, while limiting drug exposure and risks for participants. The microdose concept is based on the assumption that microdose pharmacokinetics can be extrapolated to pharmacokinetics of a therapeutic dose. However, it is unknown whether microdose pharmacokinetics are actually indicative of the pharmacokinetics at therapeutic dose. The aim of this review is to investigate the predictive value of microdose pharmacokinetics and to identify drug characteristics that may influence the scalability of these parameters. The predictive value of microdose pharmacokinetics was determined for 46 compounds and showed adequate predictability for 28 of 41 orally administered drugs (68%) and 15 of 16 intravenously administered drugs (94%). Microdose pharmacokinetics were considered predictive if the mean observed values of the microdose and the therapeutic dose were within twofold. Nonlinearity may be caused by saturation of enzyme and transporter systems, such as intestinal and hepatic efflux and uptake transporters. The high degree of success regarding linear pharmacokinetics shows that phase 0 microdose trials can be used as an early human model for determination of drug pharmacokinetics.

[1]  Shiew-Mei Huang,et al.  Scientific perspectives on drug transporters and their role in drug interactions. , 2006, Molecular pharmaceutics.

[2]  Malcolm Rowland,et al.  Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[3]  J. Kim,et al.  The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. , 2009, Clinical therapeutics.

[4]  S. Masuda,et al.  Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. , 2005, Drug metabolism and pharmacokinetics.

[5]  P. Reeves,et al.  Metabolism of atenolol in man. , 1978, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  M. Rowland.  Microdosing of protein drugs , 2016, Clinical pharmacology and therapeutics.

[7]  Malcolm Rowland,et al.  Commentary on ACCP Position Statement on the Use of Microdosing in the Drug Development Process , 2007, Journal of clinical pharmacology.

[8]  P. Cload.  A review of the pharmacokinetics of zidovudine in man. , 1989, The Journal of infection.

[9]  P. Neuvonen,et al.  Pharmacokinetics of metformin after intravenous and oral administration to man , 1979, European Journal of Clinical Pharmacology.

[10]  C. Flexner,et al.  Accelerator Mass Spectrometry Measurement of Intracellular Concentrations of Active Drug Metabolites in Human Target Cells In Vivo , 2010, Clinical pharmacology and therapeutics.

[11]  N. Kaplan,et al.  AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  E. Chan,et al.  Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. , 1994, British journal of clinical pharmacology.

[13]  K. Oguchi,et al.  Individual Difference in the Pharmacokinetics of a Drug, Pravastatin, in Healthy Subjects , 2003, Journal of clinical pharmacology.

[14]  Rhys D O Jones,et al.  PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach. , 2011, Journal of pharmaceutical sciences.

[15]  Kaoru Kobayashi,et al.  Identification of Human Cytochrome P450 Isozymes Involved in Diphenhydramine N-Demethylation , 2007, Drug Metabolism and Disposition.

[16]  S. Yamada,et al.  Effects of Ginkgo Biloba Extract on Pharmacokinetics and Pharmacodynamics of Tolbutamide and Midazolam in Healthy Volunteers , 2006, Journal of clinical pharmacology.

[17]  Yoshiaki Matsumoto,et al.  Pharmacokinetics/pharmacodynamics of acetaminophen analgesia in Japanese patients with chronic pain. , 2007, Biological & pharmaceutical bulletin.

[18]  Y Kumagai,et al.  Effects of a MATE Protein Inhibitor, Pyrimethamine, on the Renal Elimination of Metformin at Oral Microdose and at Therapeutic Dose in Healthy Subjects , 2011, Clinical pharmacology and therapeutics.

[19]  Doo-Yeoun Cho,et al.  High-sensitive LC-MS/MS method for the simultaneous determination of mirodenafil and its major metabolite, SK-3541, in human plasma: application to microdose clinical trials of mirodenafil. , 2013, Journal of separation science.

[20]  Ross Tonkens,et al.  An overview of the drug development process. , 2005, Physician executive.

[21]  F. Simons,et al.  Diphenhydramine: Pharmacokinetics and Pharmacodynamics in Elderly Adults, Young Adults, and Children , 1990, Journal of clinical pharmacology.

[22]  Kazuya Maeda,et al.  A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer , 2015, Cancer Chemotherapy and Pharmacology.

[23]  U. Fuhr,et al.  Cytochrome P450 2C9 phenotyping using low-dose tolbutamide , 2004, European Journal of Clinical Pharmacology.

[24]  S. Wolffram,et al.  The Influence of Single-Dose and Short-Term Administration of Quercetin on the Pharmacokinetics of Midazolam in Humans. , 2015, Journal of pharmaceutical sciences.

[25]  K. Kuwano,et al.  2- -N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist Prodrug , 2007 .

[26]  W E Haefeli,et al.  Response to “Can CYP3A Activity Be Evaluated for Drug Interaction Using a Nanogram Dose of Probe Drug?”: Evaluation of CYP3A Activity With Microdoses of Midazolam , 2014, Clinical pharmacology and therapeutics.

[27]  M. Dickson,et al.  The cost of new drug discovery and development. , 2004, Discovery medicine.

[28]  Alex Phipps,et al.  Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels , 2016, Clinical Pharmacokinetics.

[29]  B. Meibohm,et al.  Population Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.

[30]  Malcolm Rowland,et al.  Importance of target-mediated drug disposition for small molecules. , 2018, Drug discovery today.

[31]  K. Giacomini,et al.  Transporters Involved in Metformin Pharmacokinetics and Treatment Response. , 2017, Journal of pharmaceutical sciences.

[32]  R. Day,et al.  Clinical Pharmacokinetics of Metformin , 2011, Clinical pharmacokinetics.

[33]  S. Jacob,et al.  Dose translation between laboratory animals and human in preclinical and clinical phases of drug development , 2018, Drug development research.

[34]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[35]  Shiuan-Pey Lin,et al.  R- and S-Warfarin Were Transported by Breast Cancer Resistance Protein: From In Vitro to Pharmacokinetic-Pharmacodynamic Studies. , 2017, Journal of pharmaceutical sciences.

[36]  Y Kumagai,et al.  Microdose study of a P‐glycoprotein substrate, fexofenadine, using a non‐radioisotope‐labelled drug and LC/MS/MS , 2010, Journal of clinical pharmacy and therapeutics.

[37]  R. Levy,et al.  Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings. , 2017, Journal of pharmaceutical sciences.

[38]  Charlotte Hindsberger,et al.  The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen , 2011, Advances in therapy.

[39]  Yuichi Sugiyama,et al.  Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics , 2003, Clinical pharmacology and therapeutics.

[40]  K. Maeda,et al.  Establishment of a Set of Double Transfectants Coexpressing Organic Anion Transporting Polypeptide 1B3 and Hepatic Efflux Transporters for the Characterization of the Hepatobiliary Transport of Telmisartan Acylglucuronide , 2008, Drug Metabolism and Disposition.

[41]  P. Kwan,et al.  In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein. , 2010, Life sciences.

[42]  P. Welling,et al.  Pharmacokinetics of Phenobarbital Following Single and Repeated Doses , 1979, Journal of clinical pharmacology.

[43]  Eiji Uchida,et al.  Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. , 2004, British journal of clinical pharmacology.

[44]  L. Tang,et al.  Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. , 2009, Clinical therapeutics.

[45]  Microdosing vs. Therapeutic Dosing for Evaluation of Pharmacokinetic Data: A Comparative Study , 2009 .

[46]  M. Niemi,et al.  Impact of OATP transporters on pharmacokinetics , 2009, British journal of pharmacology.

[47]  Grzegorz Grynkiewicz,et al.  Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis. , 2015, British journal of clinical pharmacology.

[48]  M. Pastor-Anglada,et al.  Drug transporter pharmacogenetics in nucleoside-based therapies. , 2010, Pharmacogenomics.

[49]  F. Caruso,et al.  Celiprolol: pharmacokinetics and duration of pharmacodynamic activity. , 1985, British journal of clinical practice. Supplement.

[50]  D. Sica,et al.  Clinical Pharmacokinetics of Losartan , 2005, Clinical pharmacokinetics.

[51]  Yuichi Sugiyama,et al.  Comparison of pharmacokinetics of newly discovered aromatase inhibitors by a cassette microdosing approach in healthy Japanese subjects. , 2017, Drug metabolism and pharmacokinetics.

[52]  Tetsuhiro Yamada,et al.  2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist Prodrug , 2007, Journal of Pharmacology and Experimental Therapeutics.

[53]  M. Ghoneim,et al.  Diphenhydramine in Orientals and Caucasians , 1980, Clinical pharmacology and therapeutics.

[54]  Russ B Altman,et al.  PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses , 2015, Pharmacogenetics and genomics.

[55]  I. Kola,et al.  The State of Innovation in Drug Development , 2008, Clinical pharmacology and therapeutics.

[56]  W. Zeng,et al.  Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A , 2017, Clinical pharmacology and therapeutics.

[57]  D. Mayers,et al.  Microdose Pharmacokinetics of IDX899 and IDX989, Candidate HIV‐1 Non‐Nucleoside Reverse Transcriptase Inhibitors, Following Oral and Intravenous Administration in Healthy Male Subjects , 2009, Journal of clinical pharmacology.

[58]  Y Kumagai,et al.  Nonlinear Pharmacokinetics of Oral Quinidine and Verapamil in Healthy Subjects: A Clinical Microdosing Study , 2011, Clinical pharmacology and therapeutics.

[59]  Kazuya Maeda,et al.  CONTRIBUTION OF OATP (ORGANIC ANION-TRANSPORTING POLYPEPTIDE) FAMILY TRANSPORTERS TO THE HEPATIC UPTAKE OF FEXOFENADINE IN HUMANS , 2005, Drug Metabolism and Disposition.

[60]  C M Metzler,et al.  Pharmacokinetics and pharmacodynamics of oral diazepam: Effect of dose, plasma concentration, and time , 1992, Clinical pharmacology and therapeutics.

[61]  A. Fujimura,et al.  Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin , 2001, Clinical pharmacology and therapeutics.

[62]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[63]  Toshihiko Ikeda,et al.  Microdose pharmacogenetic study of ¹⁴C-tolbutamide in healthy subjects with accelerator mass spectrometry to examine the effects of CYP2C9∗3 on its pharmacokinetics and metabolism. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[64]  R. Giugliano,et al.  The P-glycoprotein transport system and cardiovascular drugs. , 2013, Journal of the American College of Cardiology.

[65]  Y Kumagai,et al.  Identification of the Rate‐Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study , 2011, Clinical pharmacology and therapeutics.

[66]  N. Kaplan,et al.  Safety, tolerability and pharmacokinetics of AFN-1252 administered as immediate release tablets in healthy subjects. , 2015, Future microbiology.

[67]  Malcolm Rowland,et al.  Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs , 2006, Clinical pharmacology and therapeutics.

[68]  Zeruesenay Desta,et al.  In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. , 2010, British journal of clinical pharmacology.

[69]  Kazuya Maeda,et al.  Microdosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1), and Interaction (Grapefruit Juice) Profiles of Celiprolol Following the Oral Microdose and Therapeutic Dose , 2012, Journal of clinical pharmacology.

[70]  H. Jono,et al.  Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents. , 2013, Biochemical and biophysical research communications.

[71]  Yuichi Sugiyama,et al.  Microdose clinical trial: quantitative determination of nicardipine and prediction of metabolites in human plasma. , 2009, Drug metabolism and pharmacokinetics.

[72]  Thierry Lavé,et al.  PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets. , 2011, Journal of pharmaceutical sciences.

[73]  T. Iga,et al.  Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[74]  T. Andersson.  Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors , 1996, Clinical pharmacokinetics.

[75]  Malcolm Rowland,et al.  PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. , 2011, Journal of pharmaceutical sciences.

[76]  W E Haefeli,et al.  A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions , 2013, Clinical pharmacology and therapeutics.

[77]  P. Heizmann,et al.  Excretion and metabolism of 14C-midazolam in humans following oral dosing. , 1981, Arzneimittel-Forschung.

[78]  Steven R Tannenbaum,et al.  Biphasic Elimination of Tenofovir Diphosphate and Nonlinear Pharmacokinetics of Zidovudine Triphosphate in a Microdosing Study , 2012, Journal of acquired immune deficiency syndromes.

[79]  L. Benet,et al.  Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. , 2017, Journal of pharmaceutical sciences.

[80]  M. Rawlins,et al.  Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration , 1977, European Journal of Clinical Pharmacology.

[81]  R. C. Garner,et al.  A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects. , 2009, British journal of clinical pharmacology.

[82]  M. Sari,et al.  Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. , 1991, Journal of medicinal chemistry.

[83]  U. Christians,et al.  Active transport of the angiotensin‐II antagonist losartan and its main metabolite EXP 3174 across MDCK‐MDR1 and Caco‐2 cell monolayers , 2000, British journal of pharmacology.

[84]  A. Nehlig.  Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption , 2018, Pharmacological Reviews.

[85]  Y. Ohashi,et al.  Clinical Dosage Determination of a New Aromatase Inhibitor, Anastrozole, in Postmenopausal Japanese Women with Advanced Breast Cancer , 2000 .

[86]  J. Balthasar,et al.  Mechanistic considerations for the use of monoclonal antibodies for cancer therapy , 2014, Cancer biology & medicine.

[87]  Kazuya Maeda,et al.  PREDOMINANT CONTRIBUTION OF OATP1B3 TO THE HEPATIC UPTAKE OF TELMISARTAN, AN ANGIOTENSIN II RECEPTOR ANTAGONIST, IN HUMANS , 2006, Drug Metabolism and Disposition.

[88]  A. D. Rodrigues,et al.  Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[89]  Gerd Mikus,et al.  Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. , 2015, British journal of clinical pharmacology.

[90]  Dongxiao Sun,et al.  Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors , 2010, Drug metabolism reviews.

[91]  Malcolm Rowland,et al.  Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[92]  L. Benet,et al.  Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.

[93]  Ross M Tonkens.  Breaking into clinical research. , 2005, Physician executive.

[94]  H. Kusuhara,et al.  Microdose Study of 14C‐Acetaminophen With Accelerator Mass Spectrometry to Examine Pharmacokinetics of Parent Drug and Metabolites in Healthy Subjects , 2010, Clinical pharmacology and therapeutics.

[95]  Malcolm Rowland,et al.  PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance. , 2011, Journal of pharmaceutical sciences.

[96]  Tudor I. Oprea,et al.  BDDCS Applied to Over 900 Drugs , 2011, The AAPS Journal.

[97]  J. Stangier,et al.  Pharmacokinetics of Acetaminophen and Ibuprofen When Coadministered with Telmisartan in Healthy Volunteers , 2000, Journal of clinical pharmacology.

[98]  F. Faltraco,et al.  OCT1 mediates hepatic uptake of sumatriptan and loss‐of‐function OCT1 polymorphisms affect sumatriptan pharmacokinetics , 2016, Clinical pharmacology and therapeutics.

[99]  Sheila Breidinger,et al.  Ultrasensitive liquid chromatography-tandem mass spectrometric methodologies for quantification of five HIV-1 integrase inhibitors in plasma for a microdose clinical trial. , 2012, Analytical chemistry.

[100]  B. Keely,et al.  Predicting Drug Candidate Victims of Drug-Drug Interactions, using Microdosing , 2012, Clinical Pharmacokinetics.

[101]  Y. Sugiyama,et al.  Vectorial Transport of Enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in Rat and Human Livers , 2006, Journal of Pharmacology and Experimental Therapeutics.

[102]  Alex Phipps,et al.  Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[103]  P. Beaune,et al.  Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. , 1993, Molecular pharmacology.

[104]  I. Jang,et al.  Identification of cytochrome P450 enzymes responsible for N -dealkylation of a new oral erectogenic, mirodenafil , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[105]  J Burggraaf,et al.  Microdosing of a Carbon‐14 Labeled Protein in Healthy Volunteers Accurately Predicts Its Pharmacokinetics at Therapeutic Dosages , 2015, Clinical pharmacology and therapeutics.

[106]  M. Arnaud.  Pharmacokinetics and metabolism of natural methylxanthines in animal and man. , 2011, Handbook of experimental pharmacology.

[107]  C. Meisel,et al.  Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. , 2002, Pharmacogenetics.

[108]  P. Meredith,et al.  Enalapril Clinical Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships , 1993, Clinical pharmacokinetics.

[109]  D. Greenblatt,et al.  Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. , 1990, Biopharmaceutics & drug disposition.

[110]  Jon L Ruckle,et al.  Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine. , 2008, Journal of pharmaceutical sciences.

[111]  Sieto Bosgra,et al.  To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics , 2015, Clinical Pharmacokinetics.

[112]  J. Amchin,et al.  Effect of Venlafaxine on CYP1A2‐Dependent Pharmacokinetics and Metabolism of Caffeine , 1999, Journal of clinical pharmacology.

[113]  M. Gionfriddo,et al.  Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. , 2009, Biopharmaceutics & drug disposition.

[114]  Tal Burt,et al.  Microdosing and drug development: past, present and future , 2013, Expert opinion on drug metabolism & toxicology.

[115]  R. Colin Garner,et al.  The utility of microdosing over the past 5 years , 2008, Expert opinion on drug metabolism & toxicology.

[116]  J. Wagner,et al.  Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects , 2008, Clinical pharmacology and therapeutics.

[117]  A. S. Gross,et al.  Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics , 2011, The Journal of pharmacy and pharmacology.

[118]  S. Duffull,et al.  Response to “Influence of Lean Body Weight on Anticancer Drug Clearance” , 2009 .

[119]  F. Guengerich,et al.  Oxidation of quinidine by human liver cytochrome P-450. , 1986, Molecular pharmacology.

[120]  Aiman Abrahim,et al.  A Combined Accelerator Mass Spectrometry-Positron Emission Tomography Human Microdose Study with 14C- and 11C-Labelled Verapamil , 2011, Clinical pharmacokinetics.

[121]  Prajakti A Kothare,et al.  Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. , 2014, British journal of clinical pharmacology.

[122]  Malcolm Rowland,et al.  PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. , 2011, Journal of pharmaceutical sciences.

[123]  S. Wrighton,et al.  The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.

[124]  M. Eichelbaum,et al.  Identification of P450 enzymes involved in metabolism of verapamil in humans , 1993, Naunyn-Schmiedeberg's Archives of Pharmacology.

[125]  D. Mayers,et al.  Single-Dose Escalation and Multiple-Dose Safety, Tolerability, and Pharmacokinetics of IDX899, a Candidate Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Subjects , 2009, Antimicrobial Agents and Chemotherapy.

[126]  Leslie Z Benet,et al.  Lead PK commentary: predicting human pharmacokinetics. , 2011, Journal of pharmaceutical sciences.

[127]  Yasuyoshi Watanabe,et al.  Investigation of the effect of active efflux at the blood-brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system. , 2013, Journal of pharmaceutical sciences.

[128]  Kazuya Maeda,et al.  Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose , 2011, Pharmacogenetics and genomics.

[129]  J. Dingemanse,et al.  Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag , 2015, American Journal of Cardiovascular Drugs.

[130]  A. D. Rodrigues,et al.  Organic Anion Transporter 2 Mediates Hepatic Uptake of Tolbutamide, a CYP2C9 Probe Drug , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[131]  S. Wang,et al.  Relationship of P450 2C9 genetic polymorphisms in Chinese and the pharmacokinetics of tolbutamide , 2005, Journal of clinical pharmacy and therapeutics.

[132]  Min-Ho Park,et al.  Drug–drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer , 2017, Drug design, development and therapy.

[133]  D. Greenblatt,et al.  Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. , 2005, British journal of clinical pharmacology.

[134]  D. Greenblatt,et al.  Pharmacokinetics of Diphenhydramine and a Demethylated Metabolite Following Intravenous And Oral Administration , 1986, Journal of clinical pharmacology.

[135]  J. Wagner,et al.  Bioavailability Studies of Acetaminophen and Nitrofurantoin , 1974, Journal of clinical pharmacology.

[136]  S. Schenker,et al.  Diphenhydramine disposition in chronic liver disease , 1984, Clinical pharmacology and therapeutics.

[137]  P. Chakravarty,et al.  Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[138]  Yuichi Sugiyama,et al.  An Assessment of the Oral Bioavailability of Three Ca-Channel Blockers Using a Cassette-Microdose Study: A New Strategy for Streamlining Oral Drug Development. , 2015, Journal of pharmaceutical sciences.